Victoria Socha

DocwireNews

Social Determinants of Health and Adherence to Patiromer Patients with chronic kidney disease commonly develop hyperkalemia, a serious and frequent complication that can negatively affect continuation of beneficial evidence-based therapies. Recent developments in the treatment of chronic hyperkalemia in patients with CKD include patiromer. According to Nathan Kleinman, PhD, and colleagues, the optimal use of therapies such as patiromer depends on patient adherence.Social determinants of health (SDOH) are key and may have an impact on medical conditions as well as adherence to prescription medications. Dr. Kleinman et al conduced an analysis to examine the association between SDOH and adherence to or nonuse of patiromer for the treatment of hyperkalemia. Results were reported online in <a href="https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0281775" target="_blank" rel="noopener">PLOS One</a> [doi.org/10.1371/journal.pone.0281775].The observational, retrospective, real-world claims analysis included adults with prescriptions for patiromer and available prescription data for 6 and 12 months pre- and postindex prescription data. Prescription data were obtained from Symphony Health&rsquo;s Dataverse during 2015 to 2020. Information&nbsp; on SDOH was gathered from census data. Subgroups included patients with heart failure, hyperkalemia-confounding prescriptions, and any CKD stages.Adherence was defined as &gt;80% of proportion of days covered&nbsp; (PDC) for &ge;60 days and &ge;6 months. Abandonment of patiromer was defined as a portion of reversed claims. Logistic regression controlling for similar factors and initial days&rsquo; supply were used to define abandonment models.At 60 days, 48% of patients had a patiromer PDC &gt;80%. At 6 months, 25% met that definition. There were associations between higher PDC and older age, male sex, Medicare/Medicaid coverage, prescription from a nephrologist, and receiving renin-angiotensin-aldosterone system inhibitors. There were correlations between lower PDC and higher out-of-pocket costs, unemployment, poverty, disability, and any CKD stage with comorbid heart failure. Regions with higher education and income levels had better PDC.In summary, the authors said, &ldquo;SDOH (unemployment, poverty, education, income) and health indicators (disability, comorbid CKD, heart failure) were associated with low PDC. Prescription abandonment was higher in patients with prescribed higher dose, higher out-of-pocket costs, those with disability, or designated White. Key demographic, social, and other factors play a role in drug adherence when treating life-threatening abnormalities such as hyperkalemia and may influence patient outcomes.&rdquo;

Jordana Jampel

Cutaneous Melanoma: Sun Protection Behaviors and UV Exposure in Canada

Melanoma

Leah Lawrence

Significant Cardiac Benefit Seen With Ifetroban in Patients With Duchenne Muscular Dystrophy

Neurology

Apitegromab Improved Motor Function in Type 2/3 Spinal Muscular Atrophy

Latest News

Social Determinants of Health and Adherence to Patiromer

Hyperkalemia

Results of an analysis to examine the association between SDOH and adherence to or nonuse of patiromer for the treatment of hyperkalemia. 

SDH and Adherence to Patiromer

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe